A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.
Sagman
Doron
D
Lilly Research Laboratories, Eli Lilly Canada Inc, Toronto, Ontario, Canada. sagmand@lilly.com
Lee
Bobbie
B
Chandresena
Ranjith
R
Jones
Barry
B
Brunner
Elizabeth
E
D000208:Acute Disease; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D002170:Canada / Q000453:epidemiology; D015331:Cohort Studies; D003156:Community Mental Health Services / Q000706:statistics & numerical data; D003625:Data Collection / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006296:Health Services / Q000706:statistics & numerical data; D006304:Health Status; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010555:Personality Inventory / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D012720:Severity of Illness Index; D013406:Suicide, Attempted / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine